RxDoctor Payments Data

Paul Kim, MD

Internal Medicine · White Plains, NYNPI 1205926003

Payments from drug & device makers

$1,121in general payments, 2019–2025

Across 60 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$430
  • Amgen$101
  • Pfizer$99
  • AstraZeneca$96
  • GSK$89
  • AbbVie$59
  • plus $248 from 9 others

What the payments were for

  • Food & beverage$1,121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,121 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$147,641
Medicare patients
415
Services billed
1,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$186,716
FarxigaDapagliflozin Propanediol56$46,362
TradjentaLinagliptin31$29,373
XareltoRivaroxaban37$23,345
JardianceEmpagliflozin33$21,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$21,165
EntrestoSacubitril/Valsartan26$20,500
MyrbetriqMirabegron40$18,431
JanuviaSitagliptin Phosphate22$11,747
Atorvastatin Calcium829$9,470
ExelonRivastigmine11$7,902
Rosuvastatin Calcium556$7,586
Memantine Hcl165$6,612
Rivastigmine39$5,057
ArexvyRsvpref3 Antigen/As01e/Pf14$4,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$186,716270 claims
Boehringer IngelheimTradjenta, Jardiance$58$50,84064 claims
AstraZenecaFarxiga$96$46,36256 claims
NovartisEntresto, Exelon$13$28,40137 claims
GSKTrelegy Ellipta, Arexvy$89$25,66537 claims
Johnson & JohnsonXarelto$48$23,34537 claims
Astellas Pharma US IncMyrbetriq$20$18,43140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →